Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives

IntroductionDiffuse Low-grade gliomas (DLGG, WHO Grade II) are a heterogenous group of tumors comprising 13–16% of glial tumors. While maximal safe resection is endorsed as the best approach to DLGG, compared to more conservative interventions like stereotactic biopsy, the added costs and risks have...

詳細記述

書誌詳細

出版年:	Frontiers in Surgery
主要な著者:	Kyle Tuohy, Djibril M. Ba, Debarati Bhanja, Douglas Leslie, Guodong Liu, Alireza Mansouri
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2023-02-01
主題:	low-grade glioma (WHO grade II) cost resection stereotactic biopsy adverse events—complications MarketScan database
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fsurg.2023.1001741/full